MYLERAN IN TREATMENT OF CHRONIC MYELOID LEUKAEMIA

[1] GALTON DAG, 1955, LANCET, V1, P425

[2] GALTON DAG, 1953, LANCET, V1, P208

[3] HADDOW A, 1953, LANCET, V1, P207

[4] HANSEN PB, 1954, FOLIA CLIN INT BARCE, V4, P267

[5] KURRLE G, 1955, MED J AUSTRALIA, V1, P636

[6] PETRAKIS NL, 1954, CANCER, V7, P383, DOI 10.1002/1097-0142(195403)7:2<383::AID-CNCR2820070225>3.0.CO

[7] 2-V

[8] MYELOCYTIC LEUKEMIA - AN ANALYSIS OF INCIDENCE, DISTRIBUTION AND FATALITY, 1910-1948 [J]. ANNALS OF INTERNAL MEDICINE, 1951, 35 (01) : 194 - 212

[9] VIDEBAEK A, 1955, ACTA MED SCAND, V151, P295

[1] GALTON DAG, 1955, LANCET, V1, P425

[2] GALTON DAG, 1953, LANCET, V1, P208

[3] HADDOW A, 1953, LANCET, V1, P207

[4] HANSEN PB, 1954, FOLIA CLIN INT BARCE, V4, P267

[5] KURRLE G, 1955, MED J AUSTRALIA, V1, P636

[6] PETRAKIS NL, 1954, CANCER, V7, P383, DOI 10.1002/1097-0142(195403)7:2<383::AID-CNCR2820070225>3.0.CO

[7] 2-V

[8] MYELOCYTIC LEUKEMIA - AN ANALYSIS OF INCIDENCE, DISTRIBUTION AND FATALITY, 1910-1948 [J]. ANNALS OF INTERNAL MEDICINE, 1951, 35 (01) : 194 - 212

[9] VIDEBAEK A, 1955, ACTA MED SCAND, V151, P295